ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON

GHENT, Belgium, 7 September 2017
-

Ablynx
[Euronext Brussels: ABLX; OTC: ABYLY]

today announces that it will participate in the following upcoming investor conferences taking place in London, UK:

• J.P. Morgan's London Small/Mid Cap Conference
  : one-on-one meetings with institutional investors are scheduled for Thursday
  14 September 2017
  .
  
  
   
• Bank of America Merrill Lynch (BAML) Global Healthcare Conference:
  a presentation is scheduled for Friday
  15 September 2017
  at 01.45 p.m. GMT (02.45 p.m. Central European Time), followed by a breakout session, together with one-on-one meetings with institutional investors. The slides will be available, shortly after the presentation is given, on the Company's website, under the
  News & Events
  section.

About Ablynx

Ablynx
is a biopharmaceutical company engaged in the development of
Nanobodies
, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes
in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com
.

For more information, please contact


Ablynx:


Dr Edwin Moses


CEO


t:   +32 (0)9 262 00 07


m: +32 (0)473 39 50 68


e: 
edwin.moses@ablynx.com

Lies Vanneste


Director Investor Relations


t:   +32 (0)9 262 01 37


m: +32 (0)498 05 35 79


e: 
lies.vanneste@ablynx.com

Follow us on
Twitter @AblynxABLX

Ablynx media relations:


Consilium Strategic Communications


Mary-Jane Elliott, Philippa Gardner, Sukaina Virji


t: +44 (0)20 3709 5700




e:
ablynx@consilium-comms.com